TY  - JOUR
T1  - Remote ischaemic preconditioning in orthotopic liver transplantation (RIPCOLT trial): a pilot randomized controlled feasibility study
A1  - Robertson, Francis P.
A1  - Goswami, Rup
A1  - Wright, Graham P.
A1  - Imber, Charles
A1  - Sharma, Dinesh
A1  - Malago, Massimo
A1  - Fuller, Barry J.
A1  - Davidson, Brian R.
Y1  - 2017///
PB  - International Hepato-Pancreato-Biliary Association Inc.
JF  - Hpb
VL  - 19
IS  - 9
SP  - 757
EP  - 767
DO  - 10.1016/j.hpb.2017.05.005
UR  - http://dx.doi.org/10.1016/j.hpb.2017.05.005
L1  - file:///D:/OneDrive/documentos/documentos diana/Articulos finales/Remote ischaemic preconditioning in orthotopic liver transplantation (RIPCOLT trial) a pilot randomized controlled feasibility study.pdf
N2  - Background Ischaemia Reperfusion (IR) injury is a major cause of morbidity, mortality and graft loss following Orthotopic Liver Transplantation (OLT). Utilising marginal grafts, which are more susceptible to IR injury, makes this a key research goal. Remote Ischaemic Preconditioning (RIPC) has been shown to ameliorate hepatic IR injury in experimental models. Whether RIPC can reduce IR injury in human liver transplant recipients is unknown. Methods Forty patients undergoing liver transplantation were randomized to RIPC or a sham. RIPC was induced through three 5 min cycles of alternate ischaemia and reperfusion of the left leg prior to surgery. Data on clinical outcomes was collected prospectively. Per-operative cytokine levels were measured. Results Fourty five of 51 patients approached (88%) were willing to enroll in the study. Five patients were excluded and 40 randomized, of which 20 underwent RIPC which was successfully completed in all patients. There were no complications following RIPC. Median day 3 AST levels were slightly higher in the RIPC group (221 IU vs 149 IU, p = 1.00). Conclusions RIPC is acceptable and safe in liver transplant recipients. This study has not demonstrated evidence of a reduction in short-term measures of IR injury. Longer follow up will be required and consideration of an altered protocol.
ER  - 
TY  - JOUR
T1  - The hepatic protective effects of tacrolimus as a rinse solution in liver transplantation: A meta-analysis
A1  - Guo, Tao
A1  - Lei, Junhao
A1  - Gao, Jiamin
A1  - Li, Zhen
A1  - Liu, Zhisu
Y1  - 2019///
KW  - Liver transplantation
KW  - Meta-analysis
KW  - Rinse solution
KW  - Tacrolimus
JF  - Medicine (United States)
VL  - 98
IS  - 21
SN  - 0000000000
DO  - 10.1097/MD.0000000000015809
L1  - file:///D:/OneDrive/documentos/documentos diana/Articulos finales/The hepatic protective effects of tacrolimus as a rinse solution in liver transplantation.pdf
N2  - Background: Tacrolimus was used as a rinse solution against ischaemia-reperfusion injury (IRI) in liver transplantation for years but its protective effects remain controversies. Methods: We conducted literature retrieval in electronic databases including MEDLINE, EMBASE and Cochrane Central to identify relevant randomized controlled trials (RCTs) investigating the effects of tacrolimus as a rinse solution in liver transplantation. Postoperative liver function, including alanine aminotransferase (ALT), aspartate aminotransferase (AST) and total bilirubin (TBIL), at postoperative day (POD) 1, 2 and 7 was extracted for pooled estimation. Forest plots were generated to calculate the differences between the groups. The I2 index statistic was used to assess heterogeneity. Publication bias was evaluated using funnel plots and Egger’s test. Results: Three RCTs including 70 liver transplants were evaluated in this study. Pooled estimation revealed that rinse with tacrolimus in liver transplantation did not provide hepatic protection with respect to postoperative ALT (Test Z = 1.36; P = .175), AST (Test Z = 1.70; P = .090) or TBIL (Test Z = 0.69; P = .490). Sensitivity analysis by excluding extended donor criteria (EDC) livers showed similar results. Funnel plots and Egger’s test demonstrated that there was no substantial bias. Conclusion: We may tentatively conclude that tacrolimus is ineffective for amelioration of postoperative liver function as a rinse solution in liver transplantation. Nevertheless, there is great space for future research in this area, and the potential clinical value of tacrolimus needs to be further addressed. We are expecting more evidence to support our speculations.
ER  - 
TY  - JOUR
T1  - Diagnosis, Incidence, Predictors and Management of Postreperfusion Syndrome in Pediatric Deceased Donor Liver Transplantation: A Single-Center Study
A1  - Zhang, Liang
A1  - Tian, Ming
A1  - Xue, Fushan
A1  - Zhu, Zhijun
Y1  - 2018/05//
JF  - Annals of transplantation
VL  - 23
SP  - 334
EP  - 344
DO  - 10.12659/AOT.909050
L1  - file:///C:/Users/Julian Cardenas/AppData/Local/Mendeley Ltd./Mendeley Desktop/Downloaded/Zhang et al. - 2018 - Diagnosis, Incidence, Predictors and Management of Postreperfusion Syndrome in Pediatric Deceased Donor Liver Tran.pdf
N2  - BACKGROUND Postreperfusion syndrome (PRS) is a dreadful and well-documented complication in adult liver transplantation (LT). However, information regarding PRS in pediatric LT is still scarce. We aimed to identify the incidence, risk factors and associated outcomes of pediatric LT in a single-center study. MATERIAL AND METHODS The medical records of 75 consecutive pediatric patients who underwent deceased donor liZhang, L., Tian, M., Xue, F., & Zhu, Z. (2018). Diagnosis, Incidence, Predictors and Management of Postreperfusion Syndrome in Pediatric Deceased Donor Liver Transplantation: A Single-Center Study. Annals of Transplantation, 23, 334–344. https://doi.org/10.12659/AOT.909050ver transplantation (DDLT) from July 2015 to October 2017 were retrospectively reviewed. PRS was determined according to the Peking criteria when significant arrhythmia or refractory hypotension occurred following revascularization of the liver graft. Patients were divided into PRS and non-PRS groups. Preoperative, intraoperative, and postoperative data were collected and compared between the 2 groups. Independent risk factors for PRS were analyzed using binary logistic regression analysis. RESULTS PRS occurred in 26 patients (34.7%). Univariate analysis showed that the graft-to-recipient weight ratio (P=0.023), donor warm ischemia time (P<0.001), and the use of an expanded criteria donor (ECD) liver graft (P<0.001) were significant predictors of PRS. Binary logistic regression showed that the use of an ECD liver graft (odds ratio [OR]: 18.668; 95% confidence interval [95% CI]: 4.866-71.622) and lower hematocrit (HCT) level before reperfusion (OR: 0.878; 95% CI: 0.782-0.985) were independent predictors of PRS. PRS was significantly associated with early allograft dysfunction (73.1% vs. 18.4%, P<0.001), primary nonfunction (11.5% vs. 0.0%, P=0.039), and a prolonged hospital stay (median: 30.5 vs. 21.0, P=0.007). CONCLUSIONS The use of an ECD liver graft and lower HCT level before reperfusion were independent risk factors for PRS in pediatric DDLT. Intraoperative PRS occurrence seems to be associated with poor liver allograft function and worsened patient postoperative outcomes.
ER  - 
TY  - JOUR
T1  - Effects of N-acetylcysteine addition to university of Wisconsin solution on the rate of ischemia-reperfusion injury in adult orthotopic liver transplant
A1  - Aliakbarian, Mohsen
A1  - Nikeghbalian, Saman
A1  - Ghaffaripour, Sina
A1  - Bahreini, Amin
A1  - Shafiee, Mohammad
A1  - Rashidi, Mohammad
A1  - Rajabnejad, Yaser
Y1  - 2017///
KW  - Cold ischemia
KW  - Outcome
KW  - Preservative liquid
KW  - Rejection
KW  - Warm ischemia
JF  - Experimental and Clinical Transplantation
VL  - 15
IS  - 4
SP  - 432
EP  - 436
DO  - 10.6002/ect.2014.0263
L1  - file:///D:/OneDrive/documentos/documentos diana/Articulos finales/finales/Aliakbarian.pdf
N2  - Objectives: One of the main concerns in liver transplant is the prolonged ischemia time, which may lead to primary graft nonfunction or delayed function. N-acetylcysteine is known as a hepato-protective agent in different studies, which may improve human hepatocyte viability in steatotic donor livers. This study investigated whether N-acetylcysteine can decrease the rate of ischemia-reperfusion syndrome and improve short-term outcome in liver transplant recipients. Materials and Methods: This was a double-blind, randomized, control clinical trial of 115 patients. Between April 2012 and January 2013, patients with orthotopic liver transplant were randomly divided into 2 groups; in 49 cases N-acetylcysteine was added to University of Wisconsin solution as the preservative liquid (experimental group), and in 66 cases standard University of Wisconsin solution was used (control group). We compared postreperfusion hypotension, inotrope requirement before and after portal reperfusion, intermittent arterial blood gas analysis and potassium measurement, pathological review of transplanted liver, in-hospital complications, morbidity, and mortality. Results: There was no significant difference between the groups regarding time to hepatic artery reperfusion, hospital stay, vascular complications, inotrope requirement before and after portal declamping, and blood gas analysis. Hypotension after portal reperfusion was significantly more common in experimental group compared with control group (P =.005). Retransplant and in-hospital mortality were comparable between the groups. Conclusions: Preservation of the liver inside University of Wisconsin solution plus N-acetylcysteine did not change the rate of ischemia reperfusion injury and short-term outcome in liver transplant recipients.
ER  - 
TY  - JOUR
T1  - Review of nonimmunological causes for deteriorated graft function and graft loss after transplantation
A1  - Pratschke, Johann
A1  - Weiss, Sascha
A1  - Neuhaus, Peter
A1  - Pascher, Andreas
Y1  - 2008///
KW  - Chronic rejection
KW  - Non immunological factors
KW  - Organ transplantation
JF  - Transplant International
VL  - 21
IS  - 6
SP  - 512
EP  - 522
DO  - 10.1111/j.1432-2277.2008.00643.x
L1  - file:///D:/OneDrive/documentos/documentos diana/Articulos finales/Review of nonimmunological causes for deteriorated graftfunction and graft loss after transplantation.pdf
N2  - Various factors determine the graft- and patient survival after transplantation. HLA-matching and immunological factors are of importance for the short- and long-term survival. Apart from these obvious determinants, nonimmunological factors play an important role in defining the baseline organ quality as well as the recipients' status. The influence of these parameters on graft- and patient survival is still underestimated and is a topic of debate. On account of the increasing acceptance of marginal-donor organs these events are of increasing importance for graft survival and long-term function. We review nonimmunological causes for deteriorated graft function and graft loss after solid organ transplantation. © 2008 The Authors.
ER  - 
TY  - JOUR
T1  - Α-Lipoic Acid Reduces Postreperfusion Syndrome in Human Liver Transplantation - a Pilot Study
A1  - Casciato, Paola
A1  - Ambrosi, Nella
A1  - Caro, Fiorella
A1  - Vazquez, Mónica
A1  - Müllen, Eduardo
A1  - Gadano, Adrian
A1  - de Santibañes, Eduardo
A1  - de Santibañes, Martín
A1  - Zandomeni, Marcos
A1  - Chahdi, Magali
A1  - Lazarte, Julio C.
A1  - Biagiola, David A.
A1  - Iaquinandi, Juan Cruz
A1  - Santofimia-Castaño, Patricia
A1  - Iovanna, Juan
A1  - Incardona, Claudio
A1  - Chuluyan, Eduardo
Y1  - 2018///
KW  - SLPI
KW  - alpha lipoic acid
KW  - ischemia reperfusion injury
KW  - liver transplantation
KW  - postreperfusion syndrome
JF  - Transplant International
VL  - 31
IS  - 12
SP  - 1357
EP  - 1368
DO  - 10.1111/tri.13314
L1  - file:///D:/OneDrive/documentos/documentos diana/Articulos finales/finales/Casciato.pdf
N2  - A double-blind randomized controlled trial was performed to compare the safety and efficacy of α-lipoic acid (ALA) in liver transplantation (LT). The grafts were randomized to receive ALA or placebo before the cold ischemia time. Furthermore, patients transplanted with the ALA-perfused graft received 600 mg of intravenous ALA, while patients with the nonperfused graft received the placebo just before graft reperfusion. Hepatic biopsy was performed 2 h postreperfusion. Blood samples were collected before, during and 1 and 2 days after reperfusion. Quantitative polymerase chain reaction (qPCR) analysis was performed on biopsies to assess genes involved in the response to hypoxia, apoptosis, cell growth, survival and proliferation, cytokine production and tissue damage protection. Nine of 40 patients developed postreperfusion syndrome (PRS), but seven of them belonged to the control group. There was a decrease in PHD2 and an increase in alpha subunit of hypoxia-inducible factor-1 (HIF-1α) and baculoviral IAP repeat containing 2 (Birc2) transcript levels in the biopsies from the ALA-treated versus the control group of patients. Additionally, plasma levels of alarmins were lower in ALA-treated patients than control patients, which suggests that ALA-treated grafts are less inflammatory than untreated grafts. These results showed that ALA is safe for use in LT, induces gene changes that protect against hypoxia and oxidative stress and reduces the appearance of PRS.
ER  - 
TY  - JOUR
T1  - Impact of ischemic preconditioning on outcome in clinical liver surgery: A systematic review
A1  - Chu, Michael J.J.
A1  - Vather, Ryash
A1  - Hickey, Anthony J.R.
A1  - Phillips, Anthony R.J.
A1  - Bartlett, Adam S.J.R.
Y1  - 2015///
PB  - Hindawi Publishing Corporation
JF  - BioMed Research International
VL  - 2015
DO  - 10.1155/2015/370451
L1  - file:///D:/OneDrive/documentos/documentos diana/Articulos finales/Impact of ischemic preconditioning on outcome in clinical liver surgery a systematic review...pdf
N2  - Background. Ischemia-reperfusion injury is a major cause of post-liver-surgery complications. Ischemic preconditioning (IPC) has been demonstrated to protect against ischemia-reperfusion injury. Clinical studies have examined IPC in liver surgery but with conflicting results. This systematic review aimed to evaluate the effects of IPC on outcome in clinical liver surgery. Methods. An electronic search of OVID Medline and Embase databases was performed to identify studies that reported outcomes in patients undergoing liver surgery subjected to IPC. Basic descriptive statistics were used to summarise data from individual clinical studies. Results. 1093 articles were identified, of which 24 met the inclusion criteria. Seven topics were selected and analysed by subgroup. There were 10 studies in cadaveric liver transplantation, 2 in living-related liver transplantation, and 12 in liver resection. IPC decreases hepatocellular damage in liver surgery as determined by transaminases but does not translate to any significant clinical benefit in orthotopic liver transplant or liver resection. Conclusions. Available clinical evidence does not support routine use of IPC in liver surgery as it does not offer any apparent benefit in perioperative outcome. Further clinical studies will need to be carried out to determine the subset of patients that will benefit from IPC.
ER  - 
TY  - GEN
T1  - Postreperfusion syndrome: cardiovascular collapse following hepatic reperfusion during liver transplantation.
A1  - Aggarwal, S
A1  - Kang, Y
A1  - JA, Freeman
A1  - FL, Fortunato
A1  - MR, Pinsky
Y1  - 1987///
JF  - Transplantation proceedings
VL  - 19
IS  - 4 Suppl 3
SP  - 54
EP  - 55
SN  - 0041-1345
UR  - http://search.ebscohost.com/login.aspx?direct=true&db=cmedm&AN=3303534&site=eds-live
ER  - 
TY  - GEN
T1  - Postreperfusion syndrome: hypotension after reperfusion of the transplanted liver.
A1  - Aggarwal, S
A1  - Kang, Y
A1  - JA, Freeman
A1  - Jr, Fortunato F L
A1  - MR, Pinsky
Y1  - 1993///
JF  - Journal of critical care
VL  - 8
IS  - 3
SP  - 154
EP  - 160
SN  - 0883-9441
DO  - 10.1016/0883-9441(93)90021-c
UR  - http://search.ebscohost.com/login.aspx?direct=true&db=cmedm&AN=8275160&site=eds-live
ER  - 
TY  - GEN
T1  - Combined Flush With Histidine-Tryptophan-Ketoglutarate and University of Wisconsin Solutions in Liver Transplantation: Preliminary Results.
A1  - FJ, León Díaz
A1  - JL, Fernández Aguilar
A1  - S, Nicolás de Cabo
A1  - M, Pérez Reyes
A1  - B, Sánchez Pérez
A1  - C, Montiel Casado
A1  - JA, Pérez Daga
A1  - JM, Aranda Narváez
A1  - MA, Suárez Muñoz
A1  - F, Arenas González
A1  - MM, Florez Rías
A1  - JL, Pelaez Angulo
A1  - J, Santoyo Santoyo
Y1  - 2018///
JF  - Transplantation proceedings
VL  - 50
IS  - 2
SP  - 539
EP  - 542
SN  - 1873-2623
DO  - 10.1016/j.transproceed.2017.12.033
UR  - http://search.ebscohost.com/login.aspx?direct=true&db=cmedm&AN=29579846&site=eds-live
ER  - 
TY  - JOUR
T1  - Hypothermic oxygenated machine perfusion reduces bile duct reperfusion injury after transplantation of donation after circulatory death livers
A1  - van Rijn, R
A1  - van Leeuwen, O B
A1  - Matton, A P M
A1  - Burlage, L C
A1  - de Kleine, R H J
A1  - de Boer, M T
A1  - Porte, R J
A1  - Wiersema-Buist, J
A1  - van den Heuvel, M C
A1  - Gouw, A S H
Y1  - 2018///
JF  - Liver Transplantation
VL  - 24
IS  - 5
SP  - 655
EP  - 664
DO  - 10.1002/lt.25023
UR  - http://www.scopus.com/scopus/openurl/link.url?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&svc_val_fmt=info:ofi/fmt:kev:mtx:sch_svc&svc.citedby=yes&rft_id=info:eid/2-s2.0-85045004377&rfr_id=http://search.ebscohost.com&rfr_dat=partnerID:NnvIuKwx&rfr_dat=
ER  - 
TY  - JOUR
T1  - Liver Transplantation After Ex Vivo Normothermic Machine Preservation: A Phase 1 (First-in-Man) Clinical Trial
A1  - Ravikumar, R
A1  - Vogel, T
A1  - Friend, P J
A1  - Holroyd, D
A1  - Coussios, C C
A1  - Jassem, W
A1  - Heaton, N
A1  - Quaglia, A
A1  - Mergental, H
A1  - Mirza, D
A1  - Perera, M.T.P.R.
Y1  - 2016///
JF  - American Journal of Transplantation
VL  - 16
IS  - 6
SP  - 1779
EP  - 1787
DO  - 10.1111/ajt.13708
UR  - http://www.scopus.com/scopus/openurl/link.url?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&svc_val_fmt=info:ofi/fmt:kev:mtx:sch_svc&svc.citedby=yes&rft_id=info:eid/2-s2.0-84978805266&rfr_id=http://search.ebscohost.com&rfr_dat=partnerID:NnvIuKwx&rfr_dat=
ER  - 
TY  - JOUR
T1  - TREATMENT OF PARACETAMOL (ACETAMINOPHEN) POISONING WITH N-ACETYLCYSTEINE
A1  - Prescott, L F
A1  - Ballantyne, A
A1  - Proudfoot, A T
A1  - Park, J
A1  - Adriaenssens, P
Y1  - 1977///
JF  - The Lancet
VL  - 310
IS  - 8035
SP  - 432
EP  - 434
DO  - 10.1016/S0140-6736(77)90612-2
UR  - http://www.scopus.com/scopus/openurl/link.url?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&svc_val_fmt=info:ofi/fmt:kev:mtx:sch_svc&svc.citedby=yes&rft_id=info:eid/2-s2.0-0017654043&rfr_id=http://search.ebscohost.com&rfr_dat=partnerID:NnvIuKwx&rfr_dat=m
ER  - 
TY  - JOUR
T1  - Clinical results of N-acetylcysteine after major hepatic surgery: a review
A1  - McKay, Andrew
A1  - Cassidy, Darby
A1  - Sutherland, Francis
A1  - Dixon, Elijah
Y1  - 2008///
JF  - Journal of Hepato-Biliary-Pancreatic Surgery
VL  - 15
IS  - 5
SP  - 473
EP  - 478
DO  - 10.1007/s00534-007-1306-6
UR  - http://search.ebscohost.com/login.aspx?direct=true&db=edssjs&AN=edssjs.BAEB0CCA&site=eds-live
ER  - 
TY  - JOUR
T1  - N-acetylcysteine ameliorates the late phase of liver ischaemia/reperfusion injury in the rabbit with hepatic steatosis
A1  - Fusai, G
A1  - Glantzounis, G K
A1  - Hafez, T
A1  - Yang, W
A1  - Sheth, H
A1  - Kanoria, S
A1  - Seifalian, A
A1  - Davidson, B R
A1  - Quaglia, A
A1  - Parkes, H
Y1  - 2005///
JF  - Clinical Science
VL  - 109
IS  - 5
SP  - 465
EP  - 473
DO  - 10.1042/CS20050081
UR  - http://www.scopus.com/scopus/openurl/link.url?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&svc_val_fmt=info:ofi/fmt:kev:mtx:sch_svc&svc.citedby=yes&rft_id=info:eid/2-s2.0-27844514137&rfr_id=http://search.ebscohost.com&rfr_dat=partnerID:NnvIuKwx&rfr_dat=
ER  - 
TY  - GEN
T1  - Reactive species mechanisms of cellular hypoxia-reoxygenation injury.
A1  - Li, C
A1  - RM, Jackson
Y1  - 2002///
JF  - American journal of physiology. Cell physiology
VL  - 282
IS  - 2
SP  - C227
EP  - C227-41
SN  - 0363-6143
DO  - 10.1152/ajpcell.00112.2001
UR  - http://search.ebscohost.com/login.aspx?direct=true&db=cmedm&AN=11788333&site=eds-live
ER  - 
TY  - GEN
T1  - Nitric oxide in early ischaemia reperfusion injury during human orthotopic liver transplantation.
A1  - Varadarajan, R
A1  - Golden-Mason, L
A1  - Young, L
A1  - McLoughlin, P
A1  - Nolan, N
A1  - McEntee, G
A1  - Traynor, O
A1  - Geoghegan, J
A1  - JE, Hegarty
A1  - O'Farrelly, C
Y1  - 2004///
JF  - Transplantation
VL  - 78
IS  - 2
SP  - 250
EP  - 256
SN  - 0041-1337
DO  - 10.1097/01.tp.0000128188.45553.8c
UR  - http://search.ebscohost.com/login.aspx?direct=true&db=cmedm&AN=15280686&site=eds-live
ER  - 
TY  - JOUR
T1  - Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications
A1  - Berry, Cristine E
A1  - Hare, Joshua M
Y1  - 2004///
JF  - Journal of Physiology
VL  - 555
IS  - 3
SP  - 589
EP  - 590
UR  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=fulltext&D=ovft&CSC=Y&NEWS=N&SEARCH=00005245-200403160-00003.an
ER  - 
TY  - JOUR
T1  - Current strategies to minimize hepatic ischemia-reperfusion injury by targeting reactive oxygen species
A1  - Jaeschke, Hartmut
A1  - Woolbright, Benjamin L.
Y1  - 2012///
PB  - Elsevier Inc.
JF  - Transplantation Reviews
VL  - 26
IS  - 2
SP  - 103
EP  - 114
DO  - 10.1016/j.trre.2011.10.006
UR  - http://dx.doi.org/10.1016/j.trre.2011.10.006
L1  - file:///C:/Users/Julian Cardenas/Downloads/1-s2.0-S0955470X1200016X-main.pdf
N2  - Ischemia-reperfusion is a major component of injury in vascular occlusion both during liver surgery and during liver transplantation. The pathophysiology of hepatic ischemia-reperfusion includes a number of mechanisms including oxidant stress that contribute to various degrees to the overall organ damage. A large volume of recent research has focused on the use of antioxidants to ameliorate this injury, although results in experimental models have not translated well to the clinic. This review focuses on critical sources and mediators of oxidative stress during hepatic ischemia-reperfusion, the status of current antioxidant interventions, and emerging mechanisms of protection by preconditioning. While recent advances in regulation of antioxidant systems by Nrf2 provide interesting new potential therapeutic targets, an increased focus must be placed on more in-depth mechanistic investigations in hepatic ischemia-reperfusion injury and translational research in order to refine current strategies in disease management. © 2012 Elsevier Inc..
ER  - 
TY  - JOUR
T1  - Inflammatory mechanisms and therapeutic strategies for warm hepatic ischemia/reperfusion injury
A1  - Lentsch, A B
A1  - Kato, A
A1  - Yoshidome, H
A1  - McMasters, K M
A1  - Edwards, M J
Y1  - 2000///
JF  - Hepatology
VL  - 32
IS  - 2
SP  - 169
EP  - 173
DO  - 10.1053/jhep.2000.9323
UR  - http://www.scopus.com/scopus/openurl/link.url?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&svc_val_fmt=info:ofi/fmt:kev:mtx:sch_svc&svc.citedby=yes&rft_id=info:eid/2-s2.0-0033853801&rfr_id=http://search.ebscohost.com&rfr_dat=partnerID:NnvIuKwx&rfr_dat=md5:edc085a9ba6ef3928e8ad99e3464bc9e
ER  - 
TY  - JOUR
T1  - Ischemia and reperfusion-from mechanism to translation.
A1  - Eltzschig, Holger K
A1  - Eckle, Tobias
Y1  - 2011///
JF  - Nature Medicine
VL  - 17
IS  - 11
SP  - 1391
EP  - 1401
DO  - 10.1038/nm.2507
UR  - http://search.ebscohost.com/login.aspx?direct=true&db=a9h&AN=67227801&site=eds-live
ER  - 
TY  - JOUR
T1  - Liver ischemia/reperfusion injury: Processes in inflammatory networks—A review
A1  - Abu-Amara, Mahmoud
A1  - Yang, Shi Yu
A1  - Tapuria, Niteen
A1  - Fuller, Barry
A1  - Davidson, Brian
A1  - Seifalian, Alexander
Y1  - 2010///
JF  - Liver Transplantation
VL  - 16
IS  - 9
SP  - 1016
EP  - 1017
DO  - 10.1002/lt.22117
UR  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=fulltext&D=ovft&CSC=Y&NEWS=N&SEARCH=01445473-201009000-00003.an
ER  - 
TY  - GEN
T1  - Pathophysiology and related studies of the no reflow phenomenon in skeletal muscle.
A1  - DM, Allen
A1  - LE, Chen
A1  - AV, Seaber
A1  - JR, Urbaniak
Y1  - 1995///
JF  - Clinical orthopaedics and related research
IS  - 314
SP  - 122
EP  - 133
SN  - 0009-921X
UR  - http://search.ebscohost.com/login.aspx?direct=true&db=cmedm&AN=7634624&site=eds-live
ER  - 
TY  - GEN
T1  - Pathophysiology, clinical manifestations, and prevention of ischemia-reperfusion injury.
A1  - CD, Collard
A1  - Gelman, S
Y1  - 2001///
JF  - Anesthesiology
VL  - 94
IS  - 6
SP  - 1133
EP  - 1138
SN  - 0003-3022
DO  - 10.1097/00000542-200106000-00030
UR  - http://search.ebscohost.com/login.aspx?direct=true&db=cmedm&AN=11465607&site=eds-live
ER  - 
TY  - JOUR
T1  - The impact of serum potassium concentration on mortality after liver transplantation: A cohort multicenter study
A1  - Dawwas, M F
A1  - Watson, C J
A1  - Gimson, A E
A1  - Lewsey, J D
Y1  - 2009///
JF  - Transplantation
VL  - 88
IS  - 3
SP  - 402
EP  - 410
DO  - 10.1097/TP.0b013e3181aed8e4
UR  - http://www.scopus.com/scopus/openurl/link.url?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&svc_val_fmt=info:ofi/fmt:kev:mtx:sch_svc&svc.citedby=yes&rft_id=info:eid/2-s2.0-69449098529&rfr_id=http://search.ebscohost.com&rfr_dat=partnerID:NnvIuKwx&rfr_dat=md5:fc244834bd96710267f77af780d71504
ER  - 
TY  - JOUR
T1  - Sodium bicarbonate infusion in patients undergoing orthotopic liver transplantation: a single center randomized controlled pilot trial.
A1  - Weinberg, Laurence
A1  - Broad, Jeremy
A1  - Pillai, Param
A1  - Chen, Guangjun
A1  - Nguyen, Micheline
A1  - Eastwood, Glenn M
A1  - Scurrah, Nick
A1  - Nikfarjam, Mehrdad
A1  - Story, David
A1  - McNicol, Larry
A1  - Bellomo, Rinaldo
Y1  - 2016///
JF  - Clinical Transplantation
VL  - 30
IS  - 5
SP  - 556
EP  - 565
DO  - 10.1111/ctr.12721
UR  - http://search.ebscohost.com/login.aspx?direct=true&db=a9h&AN=115009016&site=eds-live
ER  - 
TY  - JOUR
T1  - Effects of metabolic acidosis on viability of cells exposed to anoxia
A1  - Bonventre, J V
A1  - Cheung, J Y
Y1  - 1985///
JF  - American Journal of Physiology - Cell Physiology
VL  - 18
IS  - 1
SP  - C149
EP  - C149 - C159
DO  - 10.1152/ajpcell.1985.249.1.c149
UR  - http://www.scopus.com/scopus/openurl/link.url?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&svc_val_fmt=info:ofi/fmt:kev:mtx:sch_svc&svc.citedby=yes&rft_id=info:eid/2-s2.0-0022098747&rfr_id=http://search.ebscohost.com&rfr_dat=partnerID:NnvIuKwx&rfr_dat=md5:3b5fbe0a02d1de31bf1521a68343d53c
ER  - 
TY  - JOUR
T1  - Intracellular pH and Ca2  homeostasis in the pH paradox of reperfusion injury to neonatal rat cardiac myocytes
A1  - Bond, J M
A1  - Chacon, E
A1  - Herman, B
A1  - Lemasters, J J
Y1  - 1993///
JF  - American Journal of Physiology - Cell Physiology
VL  - 265
IS  - 1 34-1
SP  - C129
EP  - C129 - C137
DO  - 10.1152/ajpcell.1993.265.1.c129
UR  - http://www.scopus.com/scopus/openurl/link.url?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&svc_val_fmt=info:ofi/fmt:kev:mtx:sch_svc&svc.citedby=yes&rft_id=info:eid/2-s2.0-0027259172&rfr_id=http://search.ebscohost.com&rfr_dat=partnerID:NnvIuKwx&rfr_dat=md5:ccfc7ba06d2b1b38927d41d416172302
ER  - 
TY  - JOUR
T1  - Serum acidosis prior to reperfusion facilitates hemodynamic recovery following liver transplantation
A1  - Fukazawa, Kyota
A1  - Vitin, Alexander A
A1  - Pretto  Ernesto A., Jr.
Y1  - 2016///
JF  - Journal of Anesthesia
VL  - 30
IS  - 1
SP  - 80
EP  - 88
DO  - 10.1007/s00540-015-2080-2
UR  - http://search.ebscohost.com/login.aspx?direct=true&db=edssjs&AN=edssjs.96A0BAE9&site=eds-live
ER  - 
TY  - GEN
T1  - Atropine prophylaxis of the postreperfusion syndrome in liver transplantation.
A1  - Acosta, F
A1  - Sansano, T
A1  - RF, Contreras
A1  - Reche, M
A1  - Beltran, R
A1  - Roques, V
A1  - MA, Rodriguez
A1  - Robles, R
A1  - FS, Bueno
A1  - Ramirez, P
A1  - Parrilla, P
Y1  - 1999///
JF  - Transplantation proceedings
VL  - 31
IS  - 6
SP  - 2377
EP  - 2377
SN  - 0041-1345
DO  - 10.1016/s0041-1345(99)00388-7
UR  - http://search.ebscohost.com/login.aspx?direct=true&db=cmedm&AN=10500627&site=eds-live
ER  - 
TY  - JOUR
T1  - Epinephrine and phenylephrine pretreatments for preventing postreperfusion syndrome during adult liver transplantation
A1  - Ryu, Ho-Geol
A1  - Jung, Chul-Woo
A1  - Lee, Hyung-Chul
A1  - Cho, Youn-Joung
Y1  - 2012///
JF  - Liver Transplantation
VL  - 18
IS  - 12
SP  - 1430
EP  - 1431
DO  - 10.1002/lt.23511
UR  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=fulltext&D=ovft&CSC=Y&NEWS=N&SEARCH=01445473-201212000-00005.an
ER  - 
TY  - JOUR
T1  - Goal directed preemptive ephedrine attenuates the reperfusion syndrome during adult living donor liver transplantation
A1  - Fayed, Nirmeen A
A1  - Murad, Wessam S
Y1  - 2014///
JF  - Egyptian Journal of Anaesthesia
VL  - 30
IS  - 2
SP  - 187
EP  - 195
DO  - 10.1016/j.egja.2013.10.002
UR  - http://search.ebscohost.com/login.aspx?direct=true&db=edselp&AN=S1110184913001104&site=eds-live
ER  - 
TY  - JOUR
T1  - Selective management of blunt hepatic injuries including nonoperative management is a safe and effective strategy
A1  - Christmas, Ashley Britton
A1  - Wilson, Ashley K
A1  - Manning, Benjamin
A1  - Franklin, Glen A
A1  - Miller, Frank B
A1  - Richardson, J David
A1  - Rodriguez, Jorge L
Y1  - 2005///
JF  - Surgery
VL  - 138
IS  - 4
SP  - 606
EP  - 611
DO  - 10.1016/j.surg.2005.07.018
UR  - http://search.ebscohost.com/login.aspx?direct=true&db=edselp&AN=S0039606005004204&site=eds-live
ER  - 
TY  - JOUR
T1  - Vasopressin Deficiency and Vasodilatory State in End-Stage Liver Disease
A1  - Wagener, Gebhard
A1  - Kovalevskaya, Galina
A1  - Minhaz, Moury
A1  - Mattis, Fallon
A1  - Emond, Jean C
A1  - Landry, Donald W
Y1  - 2011///
JF  - Journal of Cardiothoracic and Vascular Anesthesia
VL  - 25
IS  - 4
SP  - 665
EP  - 670
DO  - 10.1053/j.jvca.2010.09.018
UR  - http://search.ebscohost.com/login.aspx?direct=true&db=edselp&AN=S1053077010004143&site=eds-live
ER  - 
TY  - RPRT
T1  - The use of vasopressin bolus to treat refractory hypotension secondary to reperfusion during orthotopic liver transplantation.
A1  - JV, Roth
Y1  - 2006///
JF  - Anesthesia and analgesia
VL  - 103
VL  - 103
IS  - 1
SP  - 261
EP  - 261
DO  - 10.1213/01.ANE.0000215232.42488.6D
UR  - http://search.ebscohost.com/login.aspx?direct=true&db=cmedm&AN=16790680&site=eds-live
ER  - 
TY  - JOUR
T1  - Vasopressin and Methylene Blue: Alternate Therapies in Vasodilatory Shock
A1  - Lavigne, Dominique
Y1  - 2010///
JF  - Seminars in Cardiothoracic and Vascular Anesthesia
VL  - 14
IS  - 3
SP  - 186
EP  - 187
DO  - 10.1177/1089253210379271
UR  - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=fulltext&D=ovft&CSC=Y&NEWS=N&SEARCH=00127938-201009000-00005.an
ER  - 
TY  - GEN
T1  - The haemodynamic effects of the perioperative terlipressin infusion in living donor liver transplantation: A randomised controlled study
A1  - Ibrahim, Nagwa
A1  - Hasanin, Ashraf
A1  - Allah, Sabry Abd
A1  - Sayed, Eman
A1  - Afifi, Mohamed
A1  - Yassen, Khaled
A1  - Saber, Wesam
A1  - Khalil, Magdy
Y1  - 2015///
JF  - Indian Journal of Anaesthesia
VL  - 59
DO  - 10.4103/0019-5049.153037
UR  - http://search.ebscohost.com/login.aspx?direct=true&db=edsair&AN=edsair.dedup.wf.001..1645621fcef2addb0390bff0286b2af8&site=eds-live
ER  - 
TY  - JOUR
T1  - A systematic review and meta-analysis of machine perfusion vs. Static cold storage of liver allografts on liver transplantation outcomes: The future direction of graft preservation
A1  - Jia, Junjun
A1  - Nie, Yu
A1  - Li, Jianhui
A1  - Xie, Haiyang
A1  - Zhou, Lin
A1  - Yu, Jun
A1  - Zheng, Shu Sen
Y1  - 2020///
KW  - Graft preservation
KW  - Liver transplantation
KW  - Machine perfusion
KW  - Meta-analysis
KW  - Static cold storage
JF  - Frontiers in Medicine
VL  - 7
IS  - May
DO  - 10.3389/fmed.2020.00135
L1  - file:///D:/OneDrive/documentos/documentos diana/Articulos finales/A Systematic Review and Meta-Analysis of Machine Perfusion vs. Static Cold Storage of Liver Allografts on Liver Transplantation Outcomes The Future Direction of Graft Preservation.pdf
N2  - Background: Machine perfusion (MP) and static cold storage (CS) are two prevalent methods for liver allograft preservation. However, the preferred method remains controversial. Aim: To conduct a meta-analysis on the impact of MP preservation on liver transplant outcome. Methods: PubMed, EMBASE, and Cochrane Library databases were systematically searched to identify relevant trials comparing the efficacy of MP vs. CS. Odds ratios (OR) and fixed-effects models were calculated to compare the pooled data. Results: Ten prospective cohort studies and two randomized controlled trials (RCTs) were included (MP livers vs. CS livers = 315:489). Machine perfusion demonstrated superior outcomes in posttransplantation aspartate aminotransferase levels compared to CS (P < 0.05). The overall incidence of early allograft dysfunction (EAD) was significantly reduced with MP preservation than CS [OR = 0.46; 95% confidence interval (CI) = 0.31–0.67; P < 0.0001]. The incidence of total biliary complications (OR = 0.53; 95% CI = 0.34–0.83; P = 0.006) and that of ischemic cholangiopathy (OR = 0.39; 95% CI = 0.18–0.85; P = 0.02) were significantly lower in recipients with MP preservation compared with CS preservation. Hypothermic machine perfusion (HMP) but not normothermic machine perfusion (NMP) was found to significantly protect grafts from total biliary complications and ischemic cholangiopathy (P < 0.05). However, no significant differences could be detected utilizing either HMP or NMP in primary nonfunction, hepatic artery thrombosis, postreperfusion syndrome, 1-year patient survival, or 1-year graft survival (P > 0.05). Conclusions: Machine perfusion is superior to CS on improving short-term outcomes for human liver transplantation, with a less clear effect in the longer term. Hypothermic machine perfusion but not NMP conducted significantly protective effects on EAD and biliary complications. Further RCTs are warranted to confirm MP’s superiority and applications.
ER  - 
TY  - JOUR
T1  - Plasma MMP-2 and MMP-9 and their inhibitors TIMP-1 and TIMP-2 during human orthotopic liver transplantation. The effect of aprotinin and the relation to ischemia/reperfusion injury
A1  - Kuyvenhoven, Johan Ph
A1  - Molenaar, I. Quintus
A1  - Verspaget, Hein W.
A1  - Veldman, Marietta G.
A1  - Palareti, Gualtiero
A1  - Legnani, Cristina
A1  - Moolenburgh, Sanne E.
A1  - Terpstra, Onno T.
A1  - Lamers, Cornelis B.H.W.
A1  - van Hoek, Bart
A1  - Porte, Robert J.
Y1  - 2004///
KW  - Aprotinin
KW  - Ischemia/reperfusion injury
KW  - Liver transplantation
KW  - Matrix metalloproteinases
KW  - Plasmin
JF  - Thrombosis and Haemostasis
VL  - 91
IS  - 3
SP  - 506
EP  - 513
DO  - 10.1160/th03-05-0272
L1  - file:///D:/OneDrive/documentos/documentos diana/Articulos finales/Plasma MMP–2 and MMP–9 and their inhibitors TIMP-1 and TIMP-2 during human orthotopic liver transplantation.pdf
N2  - Uncontrolled activation of matrix metalloproteinases (MMPs) can result in tissue injury and inflammation, yet little is known about the activation of MMPs during orthotopic liver transplantation (OLT). OLT is associated with increased fibrinolytic activity due to elevated plasmin generation. The serine-protease plasmin not only causes degradation of fibrin clots but is also thought, amongst others, to play a role in the activation of some matrix metalloproteinases.We therefore studied the evolution of MMP-2 and -9 plasma concentrations during OLT and the effect of serine-protease inhibition by aprotinin on the level and activation of these MMPs. In a group of 24 patients who participated in a randomized, double-blind, placebo-controlled study we determined serial MMP-2 and MMP-9 plasma levels during transplantation using ELISA (total MMP), activity assays (activatable MMP) and zymography. In addition, the MMP-inhibitors TIMP-1 and TIMP-2 were assessed by ELISA. The putative regulating factors tumor necrosis factor alpha (TNF-α) and tissue-type plasminogen activator (t-PA) were assessed as well. Patients were administered high-dose aprotinin, regular-dose aprotinin or placebo during surgery. Plasma TIMP-1, TIMP-2 and MMP-2 level gradually decreased during transplantation. Approximately two-thirds of total MMP-2 appeared to be in its activatable proMMP form. No release of MMP-2 from the graft could be detected. In contrast, plasma levels of MMP-9 increased sharply during the anhepatic and postreperfusion periods. Peak MMP-9 levels of about eight times above baseline were found at 30 minutes after reperfusion. Most MMP-9 appeared to be in its active/inhibitor-complexed form. No significant differences were observed between the three treatment groups. However, in patients with more severe ischemia/reperfusion (I/R) injury the MMP-9 concentration, particularly of the active/inhibitor-complexed form, remained high at 120 minutes postreperfusion compared to patients with no or mild I/R injury. The decrease in plasma levels of MMP-2,TIMP-1 and TIMP-2 during OLT occurred irrespective of the severity of the I/R injury. There was a significant correlation between MMP-9 and t-PA levels, but not with TNF-α. In conclusion, OLT is associated with a sharp increase of MMP-9 during the anhepatic and postreperfusion periods, which coincided with the changes in t-PA. MMP-2, TIMP-1 and TIMP-2 gradually decreased during OLT. The composition of these MMPs was not altered by the use of aprotinin, suggesting that serine-protease/plasmin-independent pathways are responsible for MMP regulation during OLT. In addition, only MMP-9 seems to be involved in I/R injury during human liver transplantation. © 2004 Schattauer GmbH, Stuttgart.
ER  - 
TY  - JOUR
T1  - Effect of intraportal infusion of tacrolimus on ischaemic reperfusion injury in orthotopic liver transplantation: A randomized controlled trial
A1  - Kristo, Ivan
A1  - Wilflingseder, Julia
A1  - Kainz, Alexander
A1  - Marschalek, Julian
A1  - Wekerle, Thomas
A1  - Mühlbacher, Ferdinand
A1  - Oberbauer, Rainer
A1  - Bodingbauer, Martin
Y1  - 2011///
KW  - FK506
KW  - early graft dysfunction
KW  - functional genomics
KW  - ischaemic reperfusion injury
KW  - microarrays
KW  - molecular mechanism
JF  - Transplant International
VL  - 24
IS  - 9
SP  - 912
EP  - 919
SN  - 4314040068
DO  - 10.1111/j.1432-2277.2011.01284.x
L1  - file:///D:/OneDrive/documentos/documentos diana/Articulos finales/Effect of intraportal infusion of tacrolimus on ischaemic reperfusion injury in orthotopic liver transplantation a randomized controlled trial.pdf
N2  - The increased use of older and/or marginal donor organs in liver transplantation over the last decade calls for strategies to minimize ischaemic reperfusion (I/R) injury to prevent early graft failure. Tacrolimus, a very potent and effective calcineurin inhibitor, was selected because of its ability to ameliorate I/R injury. A randomized, blinded, controlled single-centre trial of 26 liver transplant recipients was performed between February 2008 and December 2009. Donor organs were randomized to be perfused intraportally during liver transplantation with 1.5 l 5% albumin infusion containing either 20 ng/ml tacrolimus or placebo. The primary end point was liver function as assessed by aspartate transaminase (AST) or alanine transaminase (ALT) levels 6 days after transplantation. Treatment effectiveness was tested by transcriptome-wide analysis of biopsies. There was no difference in the primary end point, i.e. AST (IU/l) and ALT (IU/l) at day 6 after transplantation between groups. Furthermore, choleastatic parameters as well as parameters of liver synthesis were not different between groups. However, tacrolimus treatment suppressed inflammation and immune response in the transplanted liver on a genome-wide basis. Intrahepatic administration of tacrolimus did not result in a reduction of AST and ALT within the first week after transplantation. © 2011 European Society for Organ Transplantation.
ER  - 
TY  - JOUR
T1  - Effect of mannitol on postreperfusion cardiac output and central venous oxygen saturation during orthotopic liver transplant: A double-blind randomized clinical trial
A1  - Sahmeddini, Mohammad
A1  - Zahiri, Siamak
A1  - Khosravi, Mohammad
A1  - Ghaffaripour, Sina
A1  - Eghbal, Mohammad
A1  - Shokrizadeh, Sakine
Y1  - 2014///
JF  - Progress in Transplantation
VL  - 24
IS  - 2
SP  - 121
EP  - 125
DO  - 10.7182/pit2014483
L1  - file:///D:/OneDrive/documentos/documentos diana/Articulos finales/finales/Sahmeddini.pdf
N2  - Context-Attenuating postreperfusion syndrome during orthotopic liver transplant is very important for transplant anesthesiologists because of the syndrome's complications. Oxygen-derived free radicals play an important role in the genesis of postreperfusion syndrome, but the effect of mannitol (a free radical scavenger) on attenuating the syndrome is unclear.Objectives-To investigate the effectiveness of infusing mannitol during the anhepatic phase in preventing postreperfusion syndrome, as indicated by postreperfusion cardiac output and central venous oxygen saturation.Design-In a randomized clinical trial, 53 patients who had undergone orthotopic liver transplant were allocated to 2 groups. During the anhepatic phase, patients in the mannitol group received 1g/kg mannitol, whereas those in the control group received physiological saline. Mean arterial pressure, cardiac output, and central venous oxygen saturation were measured before and after the portal vein was declamped. Serum levels of sodium and potassium were recorded at baseline and after portal vein declamping.Setting-Shiraz Organ Transplant Center, Shiraz, Iran.Results-In the mannitol group, no significant change was found in mean arterial pressure, cardiac output, and central venous oxygen saturation before and after declamping of the portal vein (P= .78, P= .59, and P= .83, respectively). However, after declamping in the control group, mean arterial pressure, cardiac output, and central venous oxygen saturation were significantly lower than before declamping (P=.003, P=.001, and P<.001, respectively). No significant change in serum levels of sodium and potassium from baseline to after declamping were found in either group.Conclusion-Infusion of mannitol 1 g/kg during the anhepatic phase was effective in attenuating postreperfusion syndrome without stress about hyperkalemia or hyponatremia during anesthesia. © 2014 NATCO.
ER  - 
TY  - JOUR
T1  - Hemodynamic recovery following postreperfusion syndrome in liver transplantation
A1  - Fukazawa, Kyota
A1  - Yamada, Yoshitsugu
A1  - Gologorsky, Edward
A1  - Arheart, Kristopher L.
A1  - Pretto, Ernesto A.
Y1  - 2014///
KW  - Postreperfusion syndrome
KW  - ischemia-reperfusion injury
KW  - liver transplantation
PB  - W.B. Saunders
JF  - Journal of Cardiothoracic and Vascular Anesthesia
VL  - 28
IS  - 4
SP  - 994
EP  - 1002
DO  - 10.1053/j.jvca.2014.02.017
L1  - file:///C:/Users/Julian Cardenas/AppData/Local/Mendeley Ltd./Mendeley Desktop/Downloaded/Fukazawa et al. - 2014 - Hemodynamic recovery following postreperfusion syndrome in liver transplantation.pdf
N2  - Objectives The authors' current understanding of the phenomenon of significant and sustained decrease in arterial pressure following liver graft reperfusion (postreperfusion syndrome [PRS]), is derived from relatively small observational reports, and no large scale analysis of PRS exists up to date. This study investigated its incidence, risk factors, temporal course of hemodynamic recovery, and its impact on functional graft outcome. Design Retrospective observational study of 1,024 electronic records of orthotopic liver transplant recipients. Setting Major transplant center. Measurements Out of 1,024, 715 records satisfied the inclusion criteria. Data were analyzed by multivariable Cox's proportional hazard model to identify risk factors for PRS. Hemodynamic recovery patterns and functional graft outcomes were compared between the cohorts of interest (intraoperative PRS) and control (no intraoperative PRS) after propensity score-matching. Association between donor risk index and hemodynamic recovery after hepatic artery reperfusion was analyzed by a multivariable regression model. Results The overall incidence of PRS was 31.6% with associated mortality of 0.3%. Independent risk factors for PRS included older donor age, higher donor risk index, and lower central venous pressure at reperfusion. Hemodynamic recovery after PRS following portal vein reperfusion was delayed until hepatic artery reperfusion. The slope of hemodynamic recovery, expressed as %MAP/min, correlated negatively with donor risk index (p = 0.014). Immediate and 1-year graft survival rates were similar in both cohorts. Conclusions Host hemodynamic response to graft reperfusion appeared to be phasic: initial abrupt hypotension after portal vein reperfusion was followed by a period of gradual decline of blood pressure until hepatic artery reperfusion, and sustained hemodynamic recovery afterwards. The slope of hemodynamic recovery correlated negatively with the donor risk index. PRS was not associated with deterioration of post-transplant graft survival and function. © 2014 Elsevier Inc.
ER  - 
TY  - GEN
T1  - Post reperfusion syndrome during liver transplantation: From pathophysiology to therapy and preventive strategies
A1  - Siniscalchi, Antonio
A1  - Gamberini, Lorenzo
A1  - Laici, Cristiana
A1  - Bardi, Tommaso
A1  - Ercolani, Giorgio
A1  - Lorenzini, Laura
A1  - Faenza, Stefano
Y1  - 2016/01//
KW  - Drug therapy
KW  - Hemodynamics
KW  - Ischemiareperfusion injury
KW  - Liver transplantation
KW  - Reperfusion
PB  - Baishideng Publishing Group Co., Limited
JF  - World Journal of Gastroenterology
VL  - 22
IS  - 4
SP  - 1551
EP  - 1569
DO  - 10.3748/wjg.v22.i4.1551
L1  - file:///C:/Users/Julian Cardenas/AppData/Local/Mendeley Ltd./Mendeley Desktop/Downloaded/Siniscalchi et al. - 2016 - Post reperfusion syndrome during liver transplantation From pathophysiology to therapy and preventive strate.pdf
N2  - This review aims at evaluating the existing evidence regarding post reperfusion syndrome, providing a description of the pathophysiologic mechanisms involved and possible management and preventive strategies. A PubMed search was conducted using the MeSH database, "Reperfusion" AND "liver transplantation" were the combined MeSH headings; EMBASE and the Cochrane library were also searched using the same terms. 52 relevant studies and one ongoing trial were found. The concept of post reperfusion syndrome has evolved through years to a multisystemic disorder. The implications of the main organ, recipient and procedure related factors in the genesis of this complex syndrome are discussed in the text as the novel pharmacologic and technical approaches to reduce its incidence. However the available evidence about risk factors, physiopathology and preventive measures is still confusing, the presence of two main defnitions and the numerosity of possible confounding factors greatly complicates the interpretation of the studies.
ER  - 
TY  - JOUR
T1  - Incidence and predictors of post-reperfusion syndrome in living donor liver transplantation
A1  - Chung, In S.
A1  - Kim, Ha Y.
A1  - Shin, Young H.
A1  - Ko, Justin S.
A1  - Gwak, Mi S.
A1  - Sim, Woo S.
A1  - Kim, Gaab S.
A1  - Lee, Suk Koo
Y1  - 2012/07//
KW  - Incidence
KW  - Liver transplantation
KW  - Living donor
KW  - Post-reperfusion syndrome
KW  - Risk factor
JF  - Clinical Transplantation
VL  - 26
IS  - 4
SP  - 539
EP  - 543
DO  - 10.1111/j.1399-0012.2011.01568.x
L1  - file:///C:/Users/Julian Cardenas/AppData/Local/Mendeley Ltd./Mendeley Desktop/Downloaded/Chung et al. - 2012 - Incidence and predictors of post-reperfusion syndrome in living donor liver transplantation.pdf
N2  - A characteristic pattern of hemodynamic changes that may occur in reperfusion phase of liver transplantation (LT) is known as post-reperfusion syndrome (PRS). In this study, we determined the frequency of PRS and evaluated possible predictors of PRS. The medical records of 152 patients who underwent living donor LT were reviewed. PRS was defined as a decrease in mean arterial pressure of more than 30% from the baseline value for more than onemin during the first fivemin after reperfusion. The frequency of PRS was determined, and patients were divided into two groups: PRS group and non-PRS group. Donor factors, preoperative and intraoperative recipient factors, and postoperative outcomes were compared between the two groups. PRS occurred in 58 recipients (34.2%). Preoperative model for end-stage liver disease scores of recipients and percentage of graft steatotic changes were higher in PRS group. PRS group showed higher heart rates and lower hemoglobin values preoperatively. Before reperfusion, PRS group received more transfusion and their urine output was less than that of non-PRS group. Postoperatively, peak bilirubin during the first fived after LT was higher in PRS group. In conclusion, both severity of liver disease and graft steatosis may increase risk for PRS in LT. Further prospective studies of PRS in its relationship to outcome are indicated. © 2011 John Wiley & Sons A/S.
ER  -